Boehringer Ingelheim

Boehringer Ingelheim is committed to researching breakthrough therapies aimed at improving the health of both humans and animals. As a globally leading biopharmaceutical company driven by research and development, the company demonstrates its value through innovation in areas with high unmet medical needs. Since its founding in 1885, Boehringer Ingelheim has remained an independent, family-owned enterprise—a fact that will not change in the long term. Across its three core business areas—human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing—the company serves over 130 regions worldwide with approximately 52,000 employees.In 2020, Boehringer Ingelheim significantly increased its R&D investment with the aim of developing innovative drugs and therapies for diseases that currently lack effective treatments. In 2020, Boehringer Ingelheim's total R&D expenditure reached 3.7 billion euros, marking the largest annual R&D investment in the company’s 136-year history. This has enabled the acceleration of next-generation medicines that save lives and improve quality of life. Its key research areas include: immunology and respiratory diseases, cardiovascular and metabolic diseases, central nervous system disorders, and oncology.